Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Thomas, Katja ^a   Schrötter, Hagen ^a   Halank, Michael ^a   Ziemssen, Tjalf ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Fingolimod; Multiple sclerosis; Pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA1A INTERFERON; CARBON MONOXIDE; FINGOLIMOD; GADOLINIUM; TADALAFIL; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ANGINA PECTORIS; ARTERY COMPRESSION; ARTICLE; BLOOD GAS ANALYSIS; BODY PLETHYSMOGRAPHY; CASE REPORT; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DIZZINESS; DRUG ELUTING STENT; DRUG SAFETY; DYSPNEA; ECHOCARDIOGRAPHY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RATE VARIABILITY; HEART RIGHT BUNDLE BRANCH BLOCK; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE FAILURE; HUMAN; HYPOCAPNIA; JC VIRUS; LEFT CORONARY ARTERY; LUNG ARTERY PRESSURE; LUNG CIRCULATION; LUNG DIFFUSION CAPACITY; LUNG VASCULAR RESISTANCE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEW YORK HEART ASSOCIATION CLASS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC STRESS; PHYSICAL PERFORMANCE; PULMONARY HYPERTENSION; RELAPSE; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE; TRICUSPID VALVE REGURGITATION; ANALOGS AND DERIVATIVES; COMPLICATION; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

CORONARY ARTERY DISEASE; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84902364774     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-14-126     Document Type: Article

References (14)

1. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010, 33:91-101. 10.1097/WNF.0b013e3181cbf825, 2859693, 20061941.
2. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, . Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34:1219-1263. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT).
3. Ziemssen T, Reichmann H. Cardiovascular autonomic testing in extrapyramidal disorders. J Neurol Sci 2011, 310:129-132. 10.1016/j.jns.2011.07.032, 21839477.
4. Baumruker T, Billich A, Brinkmann V. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin Investig Drugs 2007, 16:283-289. 10.1517/13543784.16.3.283, 17302523.
5. Chiba Y, Takeuchi H, Sakai H, Misawa M. Sphingosine-1-phosphate augments agonist-mediated contraction in the bronchial smooth muscles of mice. Pharmacol Rep 2011, 63:544-547.
6. Roviezzo F, D'Agostino B, Brancaleone V, De Gruttola L, Bucci M, De Dominicis G, Orlotti D, D'Aiuto E, De Palma R, Rossi F, Sorrentino R, Cirino G. Systemic administration of sphingosine-1-phosphate increases bronchial hyperresponsiveness in the mouse. Am J Respir Cell Mol Biol 2010, 42:572-577. 10.1165/rcmb.2009-0108OC, 19556602.
7. Alewijnse AE, Peters SL. Sphingolipid signalling in the cardiovascular system: good, bad or both?. Eur J Pharmacol 2008, 585:292-302. 10.1016/j.ejphar.2008.02.089, 18420192.
8. Ohmori T, Yatomi Y, Osada M, Kazama F, Takafuta T, Ikeda H, Ozaki Y. Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res 2003, 58:170-177. 10.1016/S0008-6363(03)00260-8, 12667959.
9. Thomas K, Ziemssen T. Management of fingolimod in clinical practice. Clin Neurol Neurosurg 2013, 115(Suppl 1):S60-S64.
10. Espinosa PS, Berger JR. Delayed fingolimod-associated asystole. Mult Scler 2011, 17:1387-1389. 10.1177/1352458511410344, 21652609.
11. Faber H, Fischer HJ, Weber F. Prolonged and symptomatic bradycardia following a single dose of fingolimod. Mult Scler 2013, 19:126-128. 10.1177/1352458512447596, 22729989.
12. Lindsey JW, Haden-Pinneri K, Memon NB, Buja LM. Sudden unexpected death on fingolimod. Mult Scler 2012, 18:1507-1508. 10.1177/1352458512438456, 22300970.
13. Schwarz A, Korporal M, Hosch W, Max R, Wildemann B. Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. Neurology 2010, 74:2022-2024. 10.1212/WNL.0b013e3181e3972b, 20548047.
14. Huys AC, Lalive PH, Sekoranja L. Fingolimod in a patient with Wolff-Parkinson-White syndrome. Mult Scler 2014, 20(5):636-637. 10.1177/1352458513499422, 23897641.